Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders [version 2; peer review: 1 approved, 2 approved with reservations]

Protocol for a pilot clinical trial of the senolytic drug combination Dasatinib Plus Quercetin to mitigate age-related health and cognitive decline in mental disorders [version 2; peer review: 1 approved, 2 approved with reservations]

Background Major depressive disorder (MDD) and schizophrenia are linked to accelerated aging leading to reduced lifespan, health span and cognitive decline. Cellular senescence, in which cells lose proliferative capacity and develop a senescence-associated secretory phenotype (SASP), plays a role in...

Full description

Saved in:
Bibliographic Details
Main Authors: Eric J Lenze, Andes E. Dasklakis-Perez, Julie Schweiger, Ginger Nicol, Breno Diniz, Abigail Schweiger
Format: Article
Language:English
Published: F1000 Research Ltd 2025-03-01
Series:F1000Research
Subjects:
Aging
cognitive decline
schizophrenia
depressive disorder
major
cellular senescence
eng
Online Access:https://f1000research.com/articles/13-1072/v2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://f1000research.com/articles/13-1072/v2

Similar Items